- Home
- GCMG vs DNTH Comparison
GCMG vs DNTH Comparison
Compare GCMG & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- DNTH
- Stock Information
- Founded
- GCMG 1971
- DNTH 2015
- Country
- GCMG United States
- DNTH United States
- Employees
- GCMG N/A
- DNTH N/A
- Industry
- GCMG Finance/Investors Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- GCMG Finance
- DNTH Health Care
- Exchange
- GCMG Nasdaq
- DNTH Nasdaq
- Market Cap
- GCMG 631.4M
- DNTH 651.8M
- IPO Year
- GCMG N/A
- DNTH N/A
- Fundamental
- Price
- GCMG $13.05
- DNTH $24.30
- Analyst Decision
- GCMG Buy
- DNTH Strong Buy
- Analyst Count
- GCMG 4
- DNTH 8
- Target Price
- GCMG $15.13
- DNTH $54.00
- AVG Volume (30 Days)
- GCMG 590.1K
- DNTH 362.9K
- Earning Date
- GCMG 08-07-2025
- DNTH 08-07-2025
- Dividend Yield
- GCMG 3.37%
- DNTH N/A
- EPS Growth
- GCMG N/A
- DNTH N/A
- EPS
- GCMG 0.19
- DNTH N/A
- Revenue
- GCMG $533,097,999.00
- DNTH $4,854,000.00
- Revenue This Year
- GCMG $2.72
- DNTH N/A
- Revenue Next Year
- GCMG $12.99
- DNTH N/A
- P/E Ratio
- GCMG $70.21
- DNTH N/A
- Revenue Growth
- GCMG 15.56
- DNTH 17.87
- 52 Week Low
- GCMG $10.04
- DNTH $13.37
- 52 Week High
- GCMG $14.48
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- GCMG 69.54
- DNTH 69.50
- Support Level
- GCMG $12.69
- DNTH $19.84
- Resistance Level
- GCMG $13.04
- DNTH $21.18
- Average True Range (ATR)
- GCMG 0.32
- DNTH 1.58
- MACD
- GCMG 0.04
- DNTH 0.39
- Stochastic Oscillator
- GCMG 91.18
- DNTH 89.88
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.